Product Information
SAVAYSA 30 MG TABLET is a brand product labeled by Daiichi Sankyo Inc., priced at $15.4815 per EA under NDC 65597020230. Its NADAC has been published 456 times since Oct 21, 2015.
FDA first approved this application on Jan 8, 2015.
Strength
30 mg/1
Manufacturer
Daiichi Sankyo Inc.NDC
65597020230
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
7/1/2026
Active Ingredients
EDOXABAN TOSYLATEApproval Type
New Drug (NDA)
FDA Application
NDA206316FDA Approved
1/8/2015
On Market Since
1/12/2015
Pharmacological Classes
Price Statistics
The NADAC for SAVAYSA 30 MG TABLET has been published 456 times since Oct 21, 2015, and over the history we have for it it has risen 70.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.4815 per EA |
|---|---|
| All-time high | $15.4815 (Sep 30, 2026) |
| All-time low | $9.0683 (Oct 21, 2015) |
| 52-week high | $15.4815 |
| 52-week low | $14.5678 |
| Median price | $12.4784 |
| Average price | $12.0070 |
| Largest weekly change | +8.0% (Jan 16, 2019) |
| Weeks tracked | 456 |
| Tracking since | Oct 21, 2015 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 19% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Daiichi Sankyo Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
EDOXABAN TOSYLATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Factor Xa Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SAVAYSA 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SAVAYSA 30 MG TABLET, manufactured by Daiichi Sankyo Inc., is $15.4815 per EA (NDC 65597020230), effective Sep 30, 2026.
How has the price of SAVAYSA 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for SAVAYSA 30 MG TABLET has risen 70.7%. It has been tracked across 456 weekly CMS publications since Oct 21, 2015.
What are the highest and lowest recorded NADAC prices for SAVAYSA 30 MG TABLET?
Since Oct 21, 2015, the NADAC for SAVAYSA 30 MG TABLET has ranged from a low of $9.0683 (Oct 21, 2015) to a high of $15.4815 (Sep 30, 2026), with a median of $12.4784 per EA.
Are there cheaper alternatives to SAVAYSA 30 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SAVAYSA 30 MG TABLET, is $12.4819 per EA — about 19% below SAVAYSA 30 MG TABLET.
Who manufactures SAVAYSA 30 MG TABLET?
SAVAYSA 30 MG TABLET (NDC 65597020230) is labeled by Daiichi Sankyo Inc., and CMS classifies it as a brand product.